Idarubicin in combination with Ara-C and VP16 for treatment of refractory acute myelocytic leukemia

VernacularTitle:国产去甲氧柔红霉素联合阿糖胞苷和依托泊苷治疗难治性急性髓系白血病17例
Author: Zhongguang CUI ; Hongyi WANG ; Hongguo ZHAO ; Wei WANG
Publication Type:Journal Article
Keywords: Leukemia,myloid,acute; Drug therapy,combination
From: Journal of Leukemia & Lymphoma 2009;18(7):417-418
CountryChina
Language:Chinese
Abstract: Objective To investigate the curative effect of the Idarubicin(IDA) in combination with Am-Cand VP16 (IAE) regimen for treatment on refractory acute myelecytic leukemia. Methods Idarubiein 7 mg/m2 iv gtt for 3 days, Ara-C 100 mg/m2 and VP16 100 mg/d iv gtt for 5 days continuously were used as one course.Results Among 17 refractory leukemia patients complete remission was achieved in 9 patients and partial remission in 4 patients, but no remission in 3 patients and one patient died of cerebral hemorrhage after one-two courses of the treatment. Conclusion The IAE regimen for treatment of refractory acute myelocytic leukemia is an effective therapy. The major toxic side effects encountered were marrow suppression,neutropenia and thrombocytopenia. The toxic side effects in heart, liver and kidney were not found.